Related Experiment Video
Updated: Dec 25, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
UbcH10 a Major Actor in Cancerogenesis and a Potential Tool for Diagnosis and Therapy
Ivan Presta1, Fabiana Novellino2, Annalidia Donato3
1Department of Health Sciences, University "Magna Græcia" of Catanzaro, 88100 Catanzaro, Italy.
Abstract:
Malignant transformation is a multistep process in which several molecular entities become dysregulated and result in dysfunction in the regulation of cell proliferation. In past years, scientists have gradually dissected the pathways involved in the regulation of the cell cycle. The mitotic ubiquitin-conjugating enzymes UbcH10, has been extensively studied since its cloning and characterization and it has been identified as a constantly overexpressed factor in many types of cancer. In this paper, we have reviewed the literature about UbcH10 in human cancer, pointing out the association between its overexpression and exacerbation of cancer phenotype. Moreover, many recalled studied demonstrated how immunohistochemistry or RT-PCR analysis can distinguish normal tissues and benign lesions from malignant neoplasms. In other experimental studies, many of the consequences of UbcH10 overexpression, such as increased proliferation, metastasizing, cancer progression and resistance to anticancer drugs are reversed through gene silencing techniques. In recent years, many authors have defined UbcH10 evaluation in cancer patients as a useful tool for diagnosis and therapy. This opinion is shared by the authors who advertise how it would be useful to start using in clinical practice the notions acquired about this important moleculein the carcinogenesis of many human malignancies.
Insights
The mitotic ubiquitin-conjugating enzyme UbcH10 is overexpressed in many cancers, driving proliferation and metastasis. Gene silencing can reverse these effects, suggesting UbcH10 as a diagnostic and therapeutic target in human malignancies.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Malignant transformation involves dysregulated cell proliferation pathways.
- The mitotic ubiquitin-conjugating enzyme UbcH10 (also known as UBE2C) is frequently overexpressed in various human cancers.
- UbcH10 plays a critical role in cell cycle regulation.
Purpose of the Study:
- To review the literature on UbcH10 in human cancer.
- To highlight the association between UbcH10 overexpression and cancer progression.
- To discuss the diagnostic and therapeutic potential of UbcH10.
Main Methods:
- Literature review of studies on UbcH10 in human cancer.
- Analysis of immunohistochemistry and RT-PCR data for UbcH10 expression.
- Review of gene silencing studies investigating UbcH10's role.
Main Results:
- UbcH10 overexpression is linked to an exacerbated cancer phenotype.
- Immunohistochemistry and RT-PCR can differentiate malignant neoplasms from normal or benign tissues based on UbcH10 levels.
- Gene silencing of UbcH10 reverses cancer-associated phenotypes like increased proliferation, metastasis, and drug resistance.
Conclusions:
- UbcH10 evaluation in cancer patients shows promise as a diagnostic and therapeutic tool.
- Clinical application of knowledge regarding UbcH10's role in carcinogenesis is advocated.
- Targeting UbcH10 could offer new strategies for cancer treatment.
More Related Videos
10:25Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
Published on: November 22, 2024
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019